At the end of last month, the first Chinese crown -producing crown disease small molecules were taken by Azf's fixed table in China, and it has successively arrived in Henan, Hainan, Xinjiang and other places.
According to the First Financial Report, Fosun Pharmaceutical announced on the evening of Thursday (August 11) that its united real biology responded to the needs of governments in various localities, and an emergency deployment of Azf's fixing will help China to resist disease. RecentlyHenan, Hainan, Xinjiang and other places have been delivered.
According to the price of the medical insurance hanging network in various places, the price of Azf's fixed table is 270 yuan per bottle (RMB, the same below, about S $ 54.8), 35 tablets per bottle, and 1mg each.The report pointed out that the price of the drug has a great advantage compared to the currently on the market.
In the process of treatment of crown disease, the approved certificate approved by Azf was used to treat adult patients with COVID-19.The usage dosage is swallowed by the entire space, 5mg each time, once a day, the course of treatment is not more than 14 days.If you take a maximum of 14 days, a course of treatment costs about 540 yuan.
The National Health and Health Commission of China and the Office of the State Administration of Traditional Chinese Medicine issued a notice on August 9 stating that the Azf fixed chip is approved in accordance with the conditions of the State Drug Administration to increase the treatment of the new type of coronary virus pneumonia.The approval opinion is to further improve the antiviral treatment plan, and after research, the drug is included in the new type of coronary virus pneumonia diagnosis and treatment plan (ninth edition).
The key three -phase registered clinical trial supported by Azf's fixed table as a crown disease drug listing shows that the drug can significantly shorten the symptoms of patients with medium -sized coronary infection, and improve patients with improvement of clinical symptoms.The proportion reaches the results of clinical excellent efficiency.In terms of inhibiting the role of virus, it can also inhibit the activity of the virus.
From the perspective of safety, the drug is generally tolerated, and the incidence of adverse events has no statistical differences with the placebo group, and there is no risk of subjects.But in real -world applications, the effect of the drug anti -coronal virus still needs to be further verified.
Report also mentioned that another crown disease oral medicine that has been approved worldwide, Phaxlovid, has been repeatedly rumored to have recovered.Regarding the reasons for Fuyang, the market is still arguing, and there is no unified statement. Some believe that it is the characteristics of the virus, and some think it is not related to taking the treatment course.
Different from Paxlovid of Pfizer belongs to the 3CL protease inhibitor, Azf's fixed table is an RDRP inhibitor. Whether the latter will have a recovery situation still needs to be observed.
